# Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients

> **NCT05622864** · PHASE1 · COMPLETED · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 106 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** HRS-9821
- **DRUG:** HRS-9821

## Key facts

- **NCT ID:** NCT05622864
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-12
- **Primary completion:** 2025-05-07
- **Final completion:** 2025-06-16
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05622864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05622864, "Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05622864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*